Recent advances of bispecific antibodies in solid tumors

Yu, Shengnan; Li, Anping; Liu, Qian; Yuan, Xun; Xu, Hanxiao; Jiao, Dechao; Pestell, Richard G.; Han, Xinwei; Wu, Kongming

doi:10.1186/s13045-017-0522-z

Journal of Hematology & Oncology

Table 1 Clinical trials of EpCAM, HER family, CEA- and PSMA-related BsAbs in solid tumors

From: Recent advances of bispecific antibodies in solid tumors

BsAb	Targets	Format	Function	Diseases	Phase	Stage	Identifier
Catumaxomab	EpCAM/CD3	Triomab	Redirect T cells and accessory cells	Ovarian cancer	II	Completed	NCT00189345
Catumaxomab	EpCAM/CD3	Triomab	Redirect T cells and accessory cells	EpCAM positive tumor, malignant ascites	II/III	Completed	NCT00836654
Catumaxomab	EpCAM/CD3	Triomab	Redirect T cells and accessory cells	Gastric cancer, adenocarcinoma	II	Completed	NCT00464893
Catumaxomab	EpCAM/CD3	Triomab	Redirect T cells and accessory cells	Gastric adenocarcinomas	II	Active, not recruiting	NCT01504256
Catumaxomab	EpCAM/CD3	Triomab	Redirect T cells and accessory cells	Ovarian cancer	II	Completed	NCT01246440
Catumaxomab	EpCAM/CD3	Triomab	Redirect T cells and accessory cells	Gastric peritoneal carcinomatosis	II	Terminated	NCT01784900
Catumaxomab	EpCAM/CD3	Triomab	Redirect T cells and accessory cells	Epithelial cancer	I	Terminated	NCT01320020
Catumaxomab	EpCAM/CD3	Triomab	Redirect T cells and accessory cells	Malignant ascites	III	Completed	NCT00822809
MT110	EpCAM/CD3	BiTE	T cell recruitment	EpCAM-positive solid tumors	I	Completed	NCT00635596
Ertumaxomab	HER2/CD3	Triomab	Redirect T cells and accessory cells	Breast cancer	II	Terminated	NCT00452140
Ertumaxomab	HER2/CD3	Triomab	Redirect T cells and accessory cells	Breast cancer	II	Terminated	NCT00522457
Ertumaxomab	HER2/CD3	Triomab	Redirect T cells and accessory cells	Her2 positive advanced solid tumors	I/II	Terminated	NCT01569412
HER2Bi-aATC	HER2/CD3	T cells armed with BsAbs	Activated T cells	Her2-positive neoplasms	I	Recruiting	NCT02662348
EGFRBi-aATC	EGFR/CD3	T cells armed with BsAbs	Activated T cells	Advanced solid tumors	I	Terminated	NCT01081808
MDX-447	EGFR/CD64	2(Fab’)	Active monocytes	Brain and central nervous system tumors	I	Completed	NCT00005813
MM-111	HER2/HER3	HSA body	Blockade of 2 receptors	HER2 amplified solid tumors	I	Completed	NCT00911898
MM-111 + Herceptin	HER2/HER3	HSA body	Blockade of 2 receptors	Breast cancer	I	Completed	NCT01097460
MCLA-128	HER2/HER3	Full Length IgG1	Blockade of 2 receptors	Malignant solid tumors	I/II	Recruiting	NCT02912949
MM-141	HER3/IGF-IR	scFv-IgG	Blockade of 2 receptors	Hepatocellular carcinoma	I	Completed	NCT01733004
MM-141	HER3/IGF-IR	scFv-IgG	Blockade of 2 receptors	Pancreatic cancer	II	Recruiting	NCT02399137
LY3164530	EGFR/MET	OrthoFab-IgG	Blockade of 2 receptors	Advanced or metastatic cancer	I	Active, not recruiting	NCT02221882
TargomiRs	EGFR/EDV	Unclear	Delivery of nanoparticles	MPM and NSCLC	I	Recruiting	NCT02369198
EGFR(V)-EDV-Dox	EGFR/EDV	Unclear	Delivery of nanoparticles	Glioblastoma	I	Recruiting	NCT02766699
AMG211	CEA/CD3	BiTE	T cell recruitment	Gastrointestinal cancer	I	Recruiting	NCT02760199
AMG211	CEA/CD3	BiTE	T cell recruitment	Gastrointestinal cancer	I	Recruiting	NCT02291614
AMG211	CEA/CD3	BiTE	T cell recruitment	Gastrointestinal adenocarcinomas	I	Recruiting	NCT01284231
RO6958688	CEA/CD3	IgG-based	T cell recruitment	CEA-positive solid tumors	I	Recruiting	NCT02324257
RO6958688+Atezolizumab	CEA/CD3	IgG-based	T cell recruitment	CEA-positive solid tumors	I	Recruiting	NCT02650713
RO6895882	CEA/IL2	ScFv-IgG	The delivery of cytokines	CEA-positive solid tumors	I	Completed	NCT02004106
TF2	CEA/HSG	Dock and lock	Radioimmunotherapy	Colorectal cancer	I	Completed	NCT00860860
TF2	CEA/ HSG	Dock and lock	Radioimmunotherapy	Small cell lung cancer	I/II	Completed	NCT01221675
TF2	CEA/ HSG	Dock and lock	Immuno-PET	Medullary thyroid carcinoma	I/II	Completed	NCT01730638
TF2	CEA/ HSG	Dock and lock	Immuno-PET	Breast carcinoma expressing CEA	I/II	Ongoing	NCT01730612
TF2	CEA/ HSG	Dock and lock	Radioimmunotherapy	Colorectal cancer	I	Terminated	NCT01273402
TF2	CEA/ HSG	Dock and lock	Immuno-PET	Colorectal cancer	II	Completed	NCT02587247
Anti-CEAxanti-DTPA	CEA/di-DTPA-131	scFv-IgG	Radioimmunotherapy	Medullary thyroid carcinoma	II	Completed	NCT00467506
BAY2010112	PSMA/CD3	BiTE	T cell recruitment	CRPC	I	ongoing	NCT01723475
MOR209/ES414	PSMA/CD3	ScFv-Fc-scFv	T cell recruitment	mCRPC	I	Recruiting	NCT02262910

The details of Table 1 derived from http://clinicaltrials.gov/

Back to article page

ISSN: 1756-8722

Contact us

General enquiries: journalsubmissions@springernature.com